Daiichi Sankyo Builds Vaccines Business Via FluMist Deal
This article was originally published in PharmAsia News
Daiichi Sankyo is adding to its vaccines portfolio in Japan through a deal to market in the country AstraZeneca's nasally administered quadrivalent flu product FluMist.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.